Table 1.
Demographic and clinical manifestations of COVID‐19 pneumonia patients
All patients (n = 184) | Symptomatic treatment (n = 17) | Arbidol (n = 30) | Lopinavir/ritonavir (n = 27) | Arbidol+ lopinavir/ritonavir (n = 25) | Interferon (n = 41) | Interferon + lopinavir/ritonavir (n = 21) | Interferon + darunavir (n = 23) | P value | |
---|---|---|---|---|---|---|---|---|---|
Age,y | 48.7 ± 15.6 | 49.0 ± 14.3 | 47.0 ± 15.6 | 49.4 ± 14.8 | 54.0 ± 15.4 | 46.2 ± 18.1 | 47.1 ± 15.3 | 50.3 ± 13.2 | .578 a |
Sex | .564 b | ||||||||
Male | 99 (54%) | 8 (47%) | 18 (60%) | 15 (56%) | 16 (64%) | 17 (42%) | 11 (52%) | 14 (61%) | |
Female | 85 (46%) | 9 (53%) | 12 (40%) | 12 (44%) | 9 (36%) | 24 (59%) | 10 (48%) | 9 (39%) | |
Duration, d | 4.0 (3.0‐7.0) | 4.0 (2.0‐6.0) | 4.0 (3.0‐6.5) | 5.0 (3.0‐8.0) | 3.0 (2.0‐6.0) | 5.0 (3.0‐8.0) | 6.0 (3.0‐9.0) | 5.0 (2.0‐7.0) | .245 c |
Clinical manifestations | |||||||||
Fever | 144 (78%) | 14 (82%) | 20 (67%) | 23 (85%) | 23 (92%) | 30 (73%) | 18 (86%) | 16 (70%) | .277 b |
Cough | 83 (45%) | 4 (24%) | 15 (50%) | 14 (52%) | 12(48%) | 21 (51%) | 5 (24%) | 12 (52%) | .174 b |
Little phlegm | 47 (26%) | 2 (12%) | 6 (20%) | 9 (33%) | 5 (20%) | 14 (34%) | 3 (14%) | 8 (35%) | .254 b |
Stuffy and runny nose | 13 (7%) | 1 (6%) | 1 (3%) | 1 (4%) | 0 (0%) | 7 (17%) | 1 (5%) | 2 (9%) | .201 d |
Chest congestion | 12 (6%) | 1 (6%) | 1 (3%) | 3 (11%) | 1 (4%) | 1 (2%) | 4 (19%) | 1 (4%) | .250 d |
Headache | 22 (12%) | 1 (6%) | 5 (17%) | 2 (7%) | 1 (4%) | 6 (15%) | 4 (19%) | 3 (13%) | .624 d |
Myalgia or fatigue | 55 (30%) | 5 (29%) | 12 (40%) | 5 (19%) | 9 (36%) | 12 (29%) | 6 (29%) | 6 (26%) | .709 b |
Note: Data are mean ± SD, n (%), and median (IQR).
Abbreviations: ANOVA, analysis of variance; COVID‐19, coronavirus disease 2019; duration, duration from illness onset to admission; IQR, interquartile range.
P value comparing groups is from ANOVA.
P value comparing groups is from χ 2 tests.
P value comparing groups is from the Kruskal‐Wallis test.
P value comparing groups is from Fisher's exact test.